Investment
Features
FeesSafety
Academy
More
Pluang+

ICOP ETF rated Buy as copper's bull market surges on strong demand and supply deficits

Analyst Insights
08 Sep 2026
Seeking Alpha
View Source
Bullish
ICOP ETF rated Buy as copper's bull market surges on strong demand and supply deficits

The iShares Copper and Metals Mining ETF (ICOP) is rated a Buy amid copper's ongoing multidecade bull market, driven by strong technical and fundamental factors. In 2026, ICOP outperformed copper futures with a 29.3% gain year-to-date, compared to copper's 16-18% rise, fueled by mining companies' expanding profit margins. Copper's bullish outlook is supported by supply-demand deficits, growth in green energy and AI data centers, and stagnant production, with China's demand playing a crucial role. Investors are advised to accumulate ICOP on price pullbacks, considering potential volatility and geopolitical risks despite the strong long-term growth thesis.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
52 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
Solana's Stocklana hackathon ends with 604 projects competing for $126K in tokenized stock trading prizes.

Solana's Stocklana hackathon ends with 604 projects competing for $126K in tokenized stock trading prizes.

The Solana Foundation concluded its Stocklana hackathon with 604 project submissions competing for a $126,000 prize pool focused on tokenized stocks that trade 24/7 on blockchain. The event tested demand for around-the-clock trading tools and debuted...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App